Celyad Oncology Sa's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Celyad Oncology Sa (CYAD) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Celyad Oncology Sa vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 1,159M combined for its competitors (0.0% combined share).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Celyad Oncology Sa vs. its Competitors, Q4 2022
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Celyad Oncology Sa reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Celyad Oncology Sa and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Celyad Oncology Sa | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (2) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Celyad Oncology Sa's competitor groups requires a Commercial License.
Celyad Oncology Sa's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Celyad Oncology Sa | - | - | - | Yes |
| Competitors combined (54) | ||||
| High-Confidence Competitors (3) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CYAD Stock Performance relative to its Competitors
CYAD Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Nuvectis Pharma inc | 282.9% | Outperformed |
| 2 | Immix Biopharma Inc | 282.9% | Outperformed |
| 3 | Longeveron Inc | 282.9% | Outperformed |
| 4 | Merus N v | 282.9% | Outperformed |
| 5 | Ovid Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Celyad Oncology Sa's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Celyad Oncology Sa
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Celyad Oncology Sa |
10.62 | 0.01 |
 Cerevel Therapeutics Holdings Inc |
8,165.22 | 0.00 |
 Praxis Precision Medicines Inc |
8,087.45 | 8.55 |
 Merus N v |
6,810.81 | 56.61 |
 Cti Biopharma Corp |
1,195.93 | 75.77 |
 Verastem Inc |
841.98 | 87.53 |
| SUBTOTAL | 29,786.56 | 1,162.83 |
Sign in to see all competitors of Celyad Oncology Sa.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Celyad Oncology Sa versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Celyad Oncology Sa's Competitors Named by the Company
Competitive relationships identified from Celyad Oncology Sa reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Arcellx Inc | Company report | 85% |
| Legend Biotech Corporation | Company report | 85% |
| Gracell Biotechnologies Inc | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| Bellicum Pharmaceuticals Inc | Company report | 85% |
| Nkarta Inc | Company report | 85% |
| Cabaletta Bio Inc | Company report | 85% |
| Adicet Bio Inc | Company report | 85% |
| Geron Corporation | Company report | 85% |
| Instil Bio Inc | Company report | 85% |
| Gamida Cell Ltd | Company report | 85% |
| Senti Biosciences Holdings Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Celyad Oncology Sa's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Celyad Oncology Sa's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Verastem Inc | Research Developing and Commercialization Drugs Segment 100.00 % |
| Ardelyx inc | Reportable 100.00 % |
| 2seventy Bio Inc | Reportable 100.00 % |
| Lenz Therapeutics Inc | Reportable 100.00 % |
| Longeveron Inc | Reportable Segment Aggregation Before Other Operating Segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Celyad Oncology Sa's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Celyad Oncology Sa | 11 | - | - |
| Cerevel Therapeutics Holdings Inc | 8,165 | 0 | -1,771,031 |
| Praxis Precision Medicines Inc | 8,087 | 50,911 | -2,018,607 |
| Merus N v | 6,811 | 539,105 | -3,629,857 |
| Cti Biopharma Corp | 1,196 | 947,113 | -865,488 |
| Verastem Inc | 842 | 858,098 | -1,987,235 |
| PEERS TOTAL | 29,776 | 323,905 | -917,056 |
Sign in to see all peers for Celyad Oncology Sa.
Celyad Oncology Sa's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Durect Corp | Europe 72.48 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Celyad Oncology Sa's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | - | 15.9x | - |
| P/B | 5.0x | 4.3x | +0.7x |
| Return on Equity | -933.72 % | industry aggregate | -951.92 % |
| Return on Invested Capital | -451.84 % | -9.83 % (avg) | -442.01 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Celyad Oncology Sa's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2020 | 2021 | 2022 |
|---|---|---|---|
| Revenue Growth | -15.06 % | - | - |
| Operating Margin | - | - | - |
| Return on Invested Capital | -19.03 % | -25.19 % | -451.84 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Celyad Oncology Sa's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 951.9 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (70.40 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-25.1% annualized).
Methodology: see Methodology: SWOT Analysis.
Celyad Oncology Sa's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Celyad Oncology Sa | 1.19 | 1.42 | 0.06 |
| Cerevel Therapeutics Holdings Inc | 3.33 | 10.31 | 0.91 |
| Praxis Precision Medicines Inc | 11.53 | 11.58 | - |
| Merus N v | 3.67 | 7.20 | - |
| Cti Biopharma Corp | 0.73 | 1.87 | - |
| Verastem Inc | 2.33 | 2.73 | 3.48 |
Sign in to see all peers for Celyad Oncology Sa.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Celyad Oncology Sa's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Celyad Oncology Sa | Q4 2022 | - | - |
| Cerevel Therapeutics Holdings Inc | Q1 2024 | - | - |
| Praxis Precision Medicines Inc | Q2 2026 | - | - |
| Merus N v | Q3 2025 | +3.2 % | - |
| Cti Biopharma Corp | Q1 2023 | +950.8 % | - |
| Verastem Inc | Q2 2026 | +1,775.4 % | - |
| PEERS TOTAL | +8.2 % | - |
Sign in to see all peers for Celyad Oncology Sa.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Celyad Oncology Sa's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Celyad Oncology Sa | Q4 2022 | - | -66.9 % |
| Cerevel Therapeutics Holdings Inc | Q1 2024 | - | -19.3 % |
| Praxis Precision Medicines Inc | Q2 2026 | - | +1,717.9 % |
| Merus N v | Q3 2025 | - | +21.0 % |
| Cti Biopharma Corp | Q1 2023 | +340.3 % | - |
| Verastem Inc | Q2 2026 | +118.0 % | - |
Sign in to see all peers for Celyad Oncology Sa.
Celyad Oncology Sa's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Celyad Oncology Sa | - | - | - |
| Cerevel Therapeutics Holdings Inc | - | - | - |
| Praxis Precision Medicines Inc | - | - | - |
| Merus N v | - | - | - |
| Cti Biopharma Corp | - | - | - |
| Verastem Inc | - | - | - |
Sign in to see all peers for Celyad Oncology Sa.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Celyad Oncology Sa's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Celyad Oncology Sa | - | 1,896.28 |
| Cerevel Therapeutics Holdings Inc | - | - |
| Praxis Precision Medicines Inc | - | 945.57 |
| Merus N v | - | 120.32 |
| Cti Biopharma Corp | - | 15.78 |
| Verastem Inc | - | 9.62 |
| PEERS AVERAGE | - | 25.62 |
Sign in to see all peers for Celyad Oncology Sa.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.